

India-US collaboration to develop treatment for neuroendocrine tumours

18 July 2023 | News

To deliver transformative treatments to patients burdened with neuroendocrine tumours



Hyderabad-based Intonation Research Laboratories has announced a research collaboration with US-based Stanford University's Innovative Medicines Accelerator (IMA), to develop treatments that target cancerous neuroendocrine tumours.

The goal of the collaboration is to reduce the time and resources it takes to translate a biomedical breakthrough into a clinically and commercially viable medicine.

Over the next two years, Intonation will collaborate on a project that originated in the laboratory of Justin Annes, MD, PhD, associate professor of endocrinology, and advanced in partnership with Mark Smith, head of medicinal chemistry at Sarafan ChEM-H in Stanford.

"Joining forces with Stanford University's Innovative Medicine Accelerator is a prime opportunity to collaboratively create innovative treatments for neuroendocrine tumours in an efficient and cost-effective way," said Dr Suresh K. Jain, Founder and Chairman of Intonation. "Our partnership with a renowned academic institution such as Stanford will reinvigorate and enhance the drug discovery ecosystem in India."